Coumarin: Carcinogenic Potency Database

Coumarin (CAS 91-64-5)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary

Rat Target Sites		Mouse Target Sites		TD₅₀ (mg/kg/day)
Male	Female	Male	Female	Rat	Mouse
kid liv	liv	lun	liv lun	39.2^m,v	103^m

Hamsters: Cancer Test Summary

Hamster Target Sites		TD₅₀ (mg/kg/day)
Male	Female	TD₅₀ (mg/kg/day)
no positive	no positive	no positive

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD₅₀) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.

Target Site Codes: kid = kidney. liv = liver. lun = lung. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.

TD₅₀: Our standardized measure of carcinogenic potency, TD₅₀, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD₅₀ value is a Harmonic Mean calculated using the TD₅₀ value from the most potent target site in each positive experiment.

Superscripts: m = There is more than one positive experiment in the species, and TD₅₀ values from each positive experiment are used in the calculation of the reported Harmonic mean of TD₅₀. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD₅₀ values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD₅₀) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD₅₀ estimation for a standard lifespan. See Methods for other details.

TD₅₀ provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD₅₀ values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Coumarin: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD₅₀; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

COUMARIN  (1,2-benzopyrone) 91-64-5
1562 H f syg eat 22m24 1340                          0    105.mg  523.mg                                   Ueno;fctx,19,353-355;1981
 liv tum ae     no dre   P=1.    -  222.mg n.s.s.   0/12    0/13    0/10
 tba mix ae     5.52gm * P<.9    -  350.mg n.s.s.   5/12    3/13    4/10
1563 H m syg eat 24m24 1340                          0    92.0mg  460.mg
 liv tum e      no dre   P=1.    -  174.mg n.s.s.   0/12    0/11    0/11
 tba mix e      603.mg * P<.04   -  212.mg n.s.s.   1/12    2/11    5/11
1564 M f b6c gav 24m24 TR422 :                       0    35.1mg  70.4mg  141.mg
 liv MXA        65.7mg Z P<.003  c  35.7mg 438.mg   8/52   27/50   31/51  (13/51)                                     liv:hpa,hpc.
 liv hpa        72.8mg Z P<.006  c  38.0mg 966.mg   8/52   26/50   29/51  (12/51)
 MXB MXB        85.5mg * P<.0005    48.1mg 302.mg  10/52   28/50   33/51   31/51                         liv:hpa,hpc; lun:a/a,a/c. C
 lun MXA        135.mg Z P<.0005 c  87.4mg 252.mg   2/52    5/50    7/51   27/51                                      lun:a/a,a/c.
 lun a/a        179.mg Z P<.0005 c  108.mg 403.mg   2/52    5/50    7/51   20/51
 lun a/c        825.mg Z P<.0005 c  355.mg 2.92gm   0/52    0/50    0/51    7/51
 for sqp        12.2gm * P<1.    e  417.mg n.s.s.   1/52    5/50    2/51    2/51
 for MXA        42.0gm * P<1.    e  376.mg n.s.s.   1/52    6/50    3/51    2/51                                      for:sqc,sqp.
 TBA MXB        198.mg * P<.2       67.2mg n.s.s.  25/52   41/50   36/51   34/51
 liv MXB        65.7mg Z P<.003     35.7mg 438.mg   8/52   27/50   31/51  (13/51)                                 liv:hpa,hpb,hpc.
 lun MXB        135.mg Z P<.0005    87.4mg 252.mg   2/52    5/50    7/51   27/51                                      lun:a/a,a/c.
1565 M m b6c gav 24m24 TR422 :                       0    35.2mg  70.5mg  141.mg
 lun MXA        241.mg Z P<.006  p  118.mg 3.20gm  14/50    9/50   15/50   25/51                                      lun:a/a,a/c.
 lun a/a        265.mg Z P<.009  p  127.mg 7.96gm  14/50    8/50   14/50   24/51
 liv hpb        632.mg Z P<.009     240.mg 16.1gm   0/50    0/50    5/50   (1/51)                                                  S
 for MXA        152.mg Z P<.04   e  59.2mg n.s.s.   2/50    9/50   (4/50    0/51)                                     for:sqc,sqp.
 for sqp        179.mg Z P<.07   e  65.3mg n.s.s.   2/50    8/50   (2/50    0/51)
 --- MXA        600.mg * P<.02      301.mg n.s.s.   0/50    3/50    4/50    4/51                          ---:hcs,mlh,mlm,mlp,mly. S
 pni isa        1.31gm * P<.03      499.mg n.s.s.   0/50    0/50    3/50    2/51                                                   S
 TBA MXB        461.mg * P<.6       86.4mg n.s.s.  42/50   40/50   42/50   39/51
 liv MXB        no dre   P=1.       137.mg n.s.s.  35/50   34/50   32/50   29/51                                  liv:hpa,hpb,hpc.
 lun MXB        241.mg Z P<.006     118.mg 3.20gm  14/50    9/50   15/50   25/51                                      lun:a/a,a/c.
1566 M f cd1 eat 25m25 2260                          0    39.0mg  130.mg  390.mg             Carlton;faat,30,145-151;1996/pers.comm.
 liv mix e      176.mg Z P<.002  -  79.5mg 598.mg   0/52    8/52   (4/52    3/52)
 lun ade e      4.50gm * P<.1    -  1.42gm n.s.s.   2/52    1/52    2/52    5/52
 lun adc e      3.14gm * P<.4    -  760.mg n.s.s.  10/52   11/52   11/52   14/52
1567 M m cd1 eat 23m23 2260                          0    36.0mg  120.mg  360.mg
 lun adc e      1.02gm * P<.04   -  417.mg n.s.s.  11/52   12/52   10/52   20/52
 liv mix e      no dre   P=1.    -  1.36gm n.s.s.  20/52   22/52   19/52   12/52
 lun ade e      no dre   P=1.    -  2.23gm n.s.s.   0/52    1/52    2/52    0/52
1568 R f f34 gav 24m24 TR422 :                       0    17.6mg  35.2mg  70.3mg
 kid rua        1.41gm * P<.07   e  347.mg n.s.s.   0/50    0/50    0/50    2/50
 TBA MXB        456.mg * P<.8       41.8mg n.s.s.  41/50   44/50   40/50   43/50
 liv MXB        no dre   P=1.       n.s.s. n.s.s.   0/50    0/50    0/50    0/50                                  liv:hpa,hpb,hpc.
1569 R f f34 gav 24m24 TR422 : with step             0    17.6mg  35.2mg  70.3mg
 kid rua        930.mg * P<.06   e  281.mg n.s.s.   0/50    0/50    1/50    2/50
1570 R m f34 gav 23m24 TR422 :                       0    17.7mg  35.3mg  71.4mg
 tes ica as     3.62mg * P<.0005    2.33mg 6.05mg  38/50   43/50   42/51   46/50                                                   S
 pit pda as     19.7mg Z P<.004     8.31mg 174.mg  19/50   12/50   16/51   (6/50)                                                  S
 for sqp as     142.mg * P<.04      24.5mg n.s.s.   0/50    1/50    0/51    1/50                                                   S
 kid MXA as     226.mg * P<.2    p  35.2mg n.s.s.   1/50    2/50    2/51    1/50                                      kid:ade,rua.
 TBA MXB as     12.0mg * P<.0005    5.71mg 47.9mg  40/50   36/50   30/51   15/50
 liv MXB as     no dre   P=1.       50.3mg n.s.s.   2/50    0/50    0/51    0/50                                  liv:hpa,hpb,hpc.
1571 R m f34 gav 23m24 TR422 : with step             0    17.7mg  35.3mg  71.4mg
 kid MXA as     13.9mg * P<.0005 p  6.49mg 37.1mg   1/50    6/50    7/51    5/50                                      kid:ade,rua.
 kid MXA as     13.9mg * P<.0005 p  6.49mg 37.1mg   1/50    6/50    7/51    5/50                                  kid:ade,rua,ruc.
 kid ruc as     151.mg * P<.2       24.7mg n.s.s.   0/50    1/50    0/51    0/50
1572 R m f34 gav 15m24 TR422a :                      0    44.6mg
 tes ica        8.22mg   P<.003     3.36mg 70.0mg  38/50   15/20                                                                   S
 kid rua        67.6mg   P<.04      12.2mg n.s.s.   1/50    2/20                                                                   S
 TBA MXB        12.2mg   P<.01      4.59mg 1.23gm  40/50   15/20
 liv MXB        171.mg   P<.4       19.3mg n.s.s.   2/50    1/20                                                  liv:hpa,hpb,hpc.
1573 R m f34 gav 15m24 TR422a : with step            0    44.6mg
 kid rua        67.6mg   P<.04      12.2mg n.s.s.   1/50    2/20                                                                   S
1574 R m f34 gav  9m24 TR422b :                      0    27.1mg
 tes ica        19.8mg   P<.3       5.48mg n.s.s.  38/50   18/20
 kid rua        234.mg   P<.5       27.3mg n.s.s.   1/50    1/20
 TBA MXB        210.mg   P<.9       9.96mg n.s.s.  40/50   14/20
 liv MXB        no dre   P=1.       51.0mg n.s.s.   2/50    0/20                                                  liv:hpa,hpb,hpc.
1575 R m f34 gav  9m24 TR422b : with step            0    27.1mg
 kid rua        43.6mg   P<.01      13.6mg 11.6gm   1/50    4/20                                                                   S
1576 R f sda eat 26m26 2260                          0    150.mg  250.mg                     Carlton;faat,30,145-151;1996/pers.comm.
 liv clc e      767.mg / P<.0005 +  467.mg 1.39gm   0/65    0/65   23/65
 liv mix e      1.44gm / P<.0005 +  758.mg 3.41gm   0/65    1/65   12/65
1577 R m sda eat 24m24 2260                          0    120.mg  200.mg
 liv clc e      302.mg / P<.0005 +  204.mg 475.mg   0/65    1/65   37/65
 liv mix e      365.mg / P<.0005 +  234.mg 659.mg   2/65    6/65   29/65

Mutagenicity in Salmonella: positive
SMILES Code for Coumarin: O=C1OC2=C(C=CC=C2)C=C1
InChI Code for Coumarin: InChI=1/C9H6O2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h1-6H
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database

Chemical Structure for Coumarin:

Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
A Screen version plot for use on a single computer screen, with the same data.
Excel version of the same data.
Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD₁₀ (LTD₁₀) are readily calculated from the TD₅₀ and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD₁₀ values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (support@leadscope.com).
Last updated: October 3, 2007

PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10